Definium Therapeutics, Inc.
DFTX
$17.64
-$0.45-2.49%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -69.12% | -71.88% | -12.23% | 38.06% | -13.52% |
| Total Depreciation and Amortization | -- | -100.00% | -100.00% | -100.00% | 1,486.84% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 32.22% | 40.42% | -81.36% | -118.09% | 48.32% |
| Change in Net Operating Assets | 382.21% | 295.21% | 170.75% | -232.85% | -153.24% |
| Cash from Operations | -66.26% | -53.26% | -37.66% | -35.96% | -22.94% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | 320.00% | 320.00% | 68.00% | -33.33% | -33.33% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 1.42% | -97.79% | -57.19% | -55.29% | 3,279.71% |
| Repurchase of Common Stock | -- | 100.00% | 100.00% | 100.00% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 1.94% | 96.87% | 47.51% | 18.81% | -1,880.69% |
| Cash from Financing | 5.56% | -90.00% | -53.10% | -55.41% | 1,058.90% |
| Foreign Exchange rate Adjustments | 76.67% | 87.50% | 123.08% | -148.84% | -137.97% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -109.14% | -255.04% | -266.15% | -237.87% | 510.10% |